Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8586862 | 0.90 | CYP2C19 (0.37) | CYP2C19POLBTDP1ALDH1A1MAPT | |
| SCHEMBL14082759 | 0.85 | CYP2C19 (0.33) | CYP2C19POLBTDP1ALDH1A1MAPT | |
| SCHEMBL7214329 | 0.85 | CYP2C19 (0.35) | CYP2C19POLBTDP1ALDH1A1MAPT | |
| SCHEMBL21645431 | 0.85 | CYP2C19 (0.35) | CYP2C19POLBTDP1ALDH1A1MAPT | |
| SCHEMBL23797334 | 0.83 | CYP2C19 (0.34) | CYP2C19POLBTDP1ALDH1A1MAPT | |
| SCHEMBL11091274 | 0.83 | CYP2C19 (0.34) | CYP2C19POLBTDP1ALDH1A1MAPT | |
| SCHEMBL27769856 | 0.82 | MEN1 (0.34) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| Hydrochloric Acid SCHEMBL29157016 | 0.81 | CYP2C19 (0.33) | CYP2C19POLBTDP1ALDH1A1MAPT | |
| SCHEMBL3258261 | 0.81 | ALDH1A1 (0.41) | POLBALDH1A1MEN1CYP1A2THRB | |
| Hydrochloric Acid SCHEMBL1273805 | 0.79 | ALDH1A1 (0.40) | POLBALDH1A1MEN1CYP1A2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3876928-B1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME LLC (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20210403479-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME CORP. (US) | 2021-12-30 | — | — | US | disclosed |
| US-20210403479-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME CORP. (US) | 2021-12-30 | — | — | US | disclosed |
| EP-3876928-A2 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | Merck Sharp & Dohme Corp. (US) | 2021-09-15 | — | — | EP | disclosed |
| US-7767828-B2 | Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV | PHENOMIX CORPORATION (US) | 2010-08-03 | — | — | US | disclosed |
| US-7576121-B2 | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV | PHENOMIX CORPORATION (US) | 2009-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403479-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | HDAC1, HDAC11, HDAC3 | CYP2C19 1511/4885POLB 1200/4885TDP1 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.